In Reply We read with interest the letter by Garcia-Ropero et al in response to our report of the MDCO-216 Infusions Leading to Changes in Atherosclerosis: a Novel Therapy in Development to Improve Cardiovascular Outcomes—Proof of Concept IVUS, Lipids, and Other Surrogate Biomarkers (MILANO-PILOT) study.1 In our article, we reported that intravenous infusions of a high-density lipoprotein (HDL) mimetic containing recombinant apolipoprotein A-I Milano did not produce incremental regression of coronary atherosclerosis in patients treated with high-intensity statins following an acute coronary syndrome. We concluded that the findings continue to fuel skepticism regarding the clinical utility of HDL-targeted therapies.1
Nicholls SJ, Puri R, Nissen SE. High-Density Lipoprotein–Targeted Therapies—Not Dead Yet—Reply. JAMA Cardiol. 2018;3(12):1255–1256. doi:https://doi.org/10.1001/jamacardio.2018.3973
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: